Mercer Global Advisors
DMAC icon

Mercer Global Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

Mercer Global Advisors’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$246 Buy
+35
New +$215 ﹤0.01% 5907

Other funds holding DMAC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Mercer Global Advisors's DMAC Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in DiaMedica Therapeutics (DMAC) in Q2 2026: 35 shares worth $246. The stake represents ﹤0.01% of the portfolio and ranks #5907 among its holdings.

58 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Mercer Global Advisors held 35 shares of DiaMedica Therapeutics worth $246 as of Q2 2026.
  • DiaMedica Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5907 holding.
  • 58 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.